CORDIS - Risultati della ricerca dell’UE
CORDIS

SinuShunt – New disruptive medical device for treatment of hydrocephalus

Descrizione del progetto

Uno shunt innovativo per trattare l’idrocefalo

L’idrocefalo è una condizione grave correlata all’accumulo di liquido cerebrospinale nel cervello. Il trattamento consiste nell’impianto di uno shunt, un dispositivo per drenare il liquido cerebrospinale nel torace o nell’addome. Il campo di applicazione del progetto SINUSHUNT, finanziato dall’UE, è sviluppare un nuovo dispositivo medico impiantabile che dreni il liquido cerebrospinale nella vena sinusale, che è il sito naturale di riassorbimento del liquido stesso. L’utilizzo dell’innovativa tecnologia dello stent supera i problemi di ostruzione associati ai drenaggi convenzionali e prolunga la durata dello shunt, riducendo la necessità di ripetere l’intervento e l’insorgenza di altre complicanze.

Obiettivo

Hydrocephalus is a devastating neurological condition caused by accumulation of cerebrospinal fluid (CSF) on brain, and If left untreated, it can be fatal. The only treatment option is surgical, either implantation of a shunting device placed centrally in the brain, or, in some cases, by use of an endoscope going through the brain substance to its central part. The main problem in the industry is that conventional treatment systems (shunts) are based on a technology from 1950s and they are failing on average in 4-8 years, due to blockage or over-drainage. This results in 100 000 re-operations annually and brings a lot of complications (incl. increased infections) to the patient. Furthermore, this inefficiency represents an additional cost of €1.5B for the health care systems annually. To offer a solution to these problems, CSF-Dynamics is developing a new disruptive implantable medical device for treatment of hydrocephalus. The main innovation is draining the cerebrospinal fluid into sinus vein that is a natural resorption place of CSF, instead of conventional chest or abdomen. The hunt system uses novel stent technology as an outlet into the sinus vein, to avoid obstruction. SinuShunt competitive advantages are: 1) significantly increased life-time of the shunt, therefore reducing amount of re-operations; 2) Better quality of life for the patient due to the close to normal drainage of the brain-fluid, avoiding over-drainage and complications thereof. Hydrocephalus market is currently valued at €1.2B and is expected to reach a value of €1.6B by 2023. The market is steadily growing at CAGR of 4.4% during this time period. The market growth is propelled by growth in aging of population, increasing awareness of the condition and constantly improving diagnostic tools. Our end-users are hydrocephalus patients and users neurosurgeons. By 2026 we expect to sell our solution internationally, employ additional 112 people, and achieve a ROI of 40.6.

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-2

Meccanismo di finanziamento

SME-2 - SME instrument phase 2

Coordinatore

CSF-DYNAMICS A/S
Contribution nette de l'UE
€ 698 862,50
Indirizzo
GAMMEL LUNDTOFTEVEJ 1 D
2800 KGS. LYNGBY
Danimarca

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 998 375,00